Maximilian Jenzer
Heidelberg University
7 Papers
Maximilian Jenzer is an academic researcher from Heidelberg University. The author has contributed to research in topics: Medicine & Immunotherapy. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
The BRCA2 mutation status shapes the immune phenotype of prostate cancer
Maximilian Jenzer,Peter Keß,Cathleen Nientiedt,Volker Endris,Maximilian Kippenberger,Jonas Leichsenring,Fabian Stögbauer,Josh Haimes,Skyler Mishkin,Brian Kudlow,Adam Kaczorowski,Stefanie Zschäbitz,Anna-Lena Volckmar,Holger Sültmann,Dirk Jäger,Anette Duensing,Peter Schirmacher,Markus Hohenfellner,Carsten Grüllich,Albrecht Stenzinger,Stefan Duensing +20 more
TL;DR: The findings provide a rationale for the future use of immune oncological approaches in BRCA2-mutated prostate cancer and may encourage efforts to target immunosuppressive T-cell populations to prime tumors for immunotherapy.
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
Thomas Walle,Sunanjay Bajaj,Joscha A. Kraske,T. Rösner,Christiane S Cussigh,Katharina A. Kälber,L. J. Müller,S.B. Strobel,Jana Burghaus,Stefan M. Kallenberger,Christoph Stein-Thöringer,Maximilian Jenzer,Antonia Schubert,Steffen Kahle,Anja Williams,Birgit Hoyler,Lin Zielske,Renate Skatula,Stefanie Sawall,Mathias F. Leber,Russell Kunes,Johannes Krisam,Carlo Fremd,Andreas Schneeweiss,Jürgen Krauss,Leonidas Apostolidis,Anne Berger,Georg Martin Haag,Stefanie Zschäbitz,Niels Halama,Christoph Springfeld,Jessica C. Hassel,Dirk Jäger,Omar Abdelrahim,Elena Busch,Patrick Derigs,Katharina Dischinger,Fouad Mitri,Kerstin Schmidt,Irfan A. Bhatti,Barbara Grün,Nicolas Hohmann,Lena Woydack,Xin-Wen Zhang,Dyke Ferber,Andreas Mock,Tillmann Pompecki,Timo Schank,Guy Ungerechts +48 more
TL;DR: In this paper , adverse events and serum cytokines in patients with 23 different tumors undergoing or not undergoing COVID-19 vaccination under ICI therapy in a prospectively planned German single-center cohort study (n = 220).
Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing.
Suranand Babu Talla,Eugen Rempel,Volker Endris,Maximilian Jenzer,Michael Allgäuer,Constantin Schwab,Daniel Kazdal,Fabian Stögbauer,Anna-Lena Volckmar,Ildiko Kocsmar,Olaf Neumann,Peter Schirmacher,Stefanie Zschäbitz,Stefan Duensing,Jan Budczies,Albrecht Stenzinger,Martina Kirchner +16 more
TL;DR: A head‐to‐head comparison of two commercially available immune gene expression assays demonstrates that focused transcript read‐outs can reliably be achieved by both technologies and that both approaches achieve comparable results despite their intrinsic technical differences.
11
Interleukin-2 and Interferon-α for Advanced Renal Cell Carcinoma: Patient Outcomes, Sexual Dimorphism of Responses, and Multimodal Treatment Approaches over a 30-Year Period
Eva Bonetti,Maximilian Jenzer,Cathleen Nientiedt,Adam Kaczorowski,Christine Geisler,Stefanie Zschäbitz,Dirk Jäger,Markus Hohenfellner,Stefan Duensing,Philipp Reimold +9 more
TL;DR: Evidence is provided that IT with s.c. IL-2 and IFN-α played a vital role in long-term survivors either by inducing lasting complete remissions or as part of multimodal approaches that allowed patients to survive until novel therapies became available.
5
Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers.
Andreas Mock,Stefanie Zschäbitz,Romy Kirsten,Matthias Scheffler,Barbara Wolf,Christel Herold-Mende,Rebecca Kramer,Elena Busch,Maximilian Jenzer,Dirk Jäger,Carsten Grüllich,Carsten Grüllich +11 more
TL;DR: It is hypothesized that nutritional supplementation with VLCFA-containing lipids might serve as an immuno sensitizer and be used as a novel predictive non-invasive biomarker for immunotherapy response and failure in urological cancer patients.